DEA Judge Paused Cannabis Rescheduling Case
The administrative law judge stayed proceedings to review a recent request to introduce a new GAO report.
Updated on Sept. 30, 2026 in Substance Abuse
Live Poll
Should federal regulators prioritize the rescheduling of marijuana to a lower tier of control?
DEA Chief Judge Derek Julius paused the high-profile cannabis rescheduling case on September 30, 2026. The stay halts the recommendation process while the court considers adding a September 23 GAO report to the official record.
Why it matters
The pause delays a final decision on whether to move marijuana from its long-standing Schedule I status under federal law. Participants requested the record be reopened to include new findings, complicating the timeline for potential administrative reclassification.
Marijuana has remained a Schedule I substance since 1970, though the Justice Department moved specific medical categories to Schedule III in April 2026. The government must file its response to the current stay request by October 13.
The players
Derek Julius
He is the DEA Chief Judge overseeing the administrative proceedings regarding the federal rescheduling of cannabis.
Justice Department
This federal executive department is responsible for enforcing laws and administering justice in the United States.
AdvisorShares Pure US Cannabis ETF
This is an exchange-traded fund that provides exposure to companies operating within the United States cannabis industry.
Trulieve Cannabis
This company is a major cannabis retailer and cultivator operating in multiple states across the United States.
The details
Judge Julius issued the stay following a September 28 filing by participants seeking to include a recent GAO study in the evidence. This procedural shift impacted financial markets, with the AdvisorShares Pure US Cannabis ETF and Trulieve Cannabis experiencing declines in extended trading.
Timeline
1970: Marijuana is formally listed as a Schedule I substance.
April 2026: The Justice Department moves medical marijuana to Schedule III.
Mid-July 2026: The public hearing for the rescheduling case concludes.
September 23, 2026: A GAO report on drug-scheduling is published.
September 30, 2026: Judge Derek Julius pauses the rescheduling proceedings.
The Big Picture
This case sits at the center of the regulatory framework established by the Controlled Substances Act. The current pause marks a significant procedural departure from the expected timeline for federal drug reclassification.
For patients using medical marijuana, the delay extends the uncertainty surrounding federal recognition and access standards. It also maintains current legal constraints for businesses operating in the medical cannabis sector.
The takeaway
The pause serves as a reminder that administrative law can significantly stall even the most high-profile legislative efforts. Readers should monitor upcoming court filings for clarity on how evidentiary requests affect regulatory timelines.
What happens next
The government is required to submit its formal response to the stay order by October 13, 2026.
Further reading
For more background on national policy shifts, visit Substance Abuse.
Live Poll
Should federal regulators prioritize the rescheduling of marijuana to a lower tier of control?
